Literature DB >> 14517714

Polymorphisms in the CYP19 and AR genes--relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy: The Danish Osteoporosis Prevention Study.

C L Tofteng1, A Kindmark, H Brändström, B Abrahamsen, S Petersen, F Stiger, L S Stilgren, J E B Jensen, P Vestergaard, B L Langdahl, L Mosekilde.   

Abstract

Polymorphisms in the androgen receptor ( AR) gene and genes encoding enzymes involved in synthesis of sex steroids (e.g., the CYP19 gene encoding aromatase) have recently received attention in osteoporosis research. In the Danish Osteoporosis Prevention Study, recent postmenopausal women were allocated to either hormone replacement therapy (HRT) or no treatment. We genotyped 1792 women for the CYP19 (TTTA)(n) repeat [short (TTTA)(n <or= 7) or long (TTTA)(n > 7)] the CYP19 C(1558)-T, and the AR (CAG)(n) repeat polymorphism [short (CAG)(n < 22), long (CAG)(n >or= 22)], and investigated associations with bone mineral density (BMD) and 5-year change in BMD. The CYP19 polymorphisms were in strong linkage disequilibrium. Perimenopausal bone mass or bone loss in untreated women was not associated with the CYP19 polymorphisms. In hormone-treated women, BMD increase in the femoral neck was highest (+0.3%/year) for long CYP19 alleles, lowest (-0.09%/year) for short alleles, and intermediate (-0.002%/year) in heterozygous women, P = 0.015. Differences were also significant in the lumbar spine, total hip, and ultradistal forearm. The C(1558)-T T-allele was associated with a more pronounced response to HRT ( P = 0.04, total hip). AR genotype was not related to BMD, but a modifying effect of sex hormone-binding globulin (SHBG) was present. In the highest SHBG quartile (SHBG > 95 nmol/1, n = 222), AR genotype was associated with baseline BMD (femoral neck: P < 0.001, total hip: P = 0.008), but without a clear gene dosage effect. We have demonstrated that polymorphisms in the CYP19 gene are associated with the magnitude of bone gain in response to HRT and that the (CAG)(n) repeat polymorphism in the AR gene is associated with bone mass in women with high levels of SHBG. These findings emphasize the complexity of the genetics of bone mass and bone loss.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14517714     DOI: 10.1007/s00223-002-2158-3

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  15 in total

1.  The genetics of response to estrogen treatment.

Authors:  Bente L Langdahl
Journal:  Clin Cases Miner Bone Metab       Date:  2009-01

Review 2.  Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells.

Authors:  Hei Jason Chan; Karineh Petrossian; Shiuan Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2015-08-13       Impact factor: 4.292

3.  Association of polymorphisms of the androgen receptor and klotho genes with bone mineral density in Japanese women.

Authors:  Yoshiji Yamada; Fujiko Ando; Naoakira Niino; Hiroshi Shimokata
Journal:  J Mol Med (Berl)       Date:  2004-11-04       Impact factor: 4.599

Review 4.  Molecular genetic studies of gene identification for osteoporosis: a 2004 update.

Authors:  Yong-Jun Liu; Hui Shen; Peng Xiao; Dong-Hai Xiong; Li-Hua Li; Robert R Recker; Hong-Wen Deng
Journal:  J Bone Miner Res       Date:  2006-10       Impact factor: 6.741

5.  CYP19A1 polymorphisms are associated with bone mineral density in Chinese men.

Authors:  Xiumei Hong; Yi-Hsiang Hsu; Henry Terwedow; Lester M Arguelles; Genfu Tang; Xue Liu; Shanchun Zhang; Xin Xu; Xiping Xu
Journal:  Hum Genet       Date:  2007-01-11       Impact factor: 4.132

6.  Effects of COLIA1 polymorphisms and haplotypes on perimenopausal bone mass, postmenopausal bone loss and fracture risk.

Authors:  N González-Bofill; L B Husted; T Harsløf; C L Tofteng; B Abrahamsen; P Eiken; P Vestergaard; B L Langdahl
Journal:  Osteoporos Int       Date:  2010-06-23       Impact factor: 4.507

7.  Bone and body composition response to testosterone therapy vary according to polymorphisms in the CYP19A1 gene.

Authors:  Lina E Aguirre; Georgia Colleluori; David Robbins; Richard Dorin; Vallabh O Shah; Rui Chen; Irum Zeb Jan; Clifford Qualls; Dennis T Villareal; Reina Armamento-Villareal
Journal:  Endocrine       Date:  2019-07-19       Impact factor: 3.633

8.  An aromatase polymorphism modulates the relationship between weight and estradiol levels in obese men.

Authors:  Ahmad Hammoud; Douglas T Carrell; A Wayne Meikle; Yuanpei Xin; Steven C Hunt; Ted D Adams; Mark Gibson
Journal:  Fertil Steril       Date:  2009-12-11       Impact factor: 7.329

9.  Polymorphisms within promoter of Japanese flounder (Paralichthys olivaceus) ovary cytochrome P450-c19 (CYP19a) gene associated with reproductive traits.

Authors:  Feng He; Hai Shen Wen; Shuang Lin Dong; Bao Shi; Cai Fang Chen; Lian Shun Wang; Jun Yao; Xing Jiang Mu; Yu Guo Zhou
Journal:  Fish Physiol Biochem       Date:  2008-06-07       Impact factor: 2.794

10.  CYP19 and ESR1 gene polymorphisms: response of the bone mineral density in post-menopausal women to hormonal replacement therapy.

Authors:  Laura Masi; Silva Ottanelli; Rossella Berni; Ettore Cacudi; Francesca Giusti; Gemma Marcucci; Loredana Cavalli; Caterina Fossi; Francesca Marini; Simone Ciuffi; Annalisa Tanini; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2014-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.